Masimo (NASDAQ:MASI) Issues FY25 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.90-$5.10 for the period, compared to the consensus EPS estimate of $4.74. Masimo also updated its FY 2024 guidance to 4.100-4.100 EPS.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MASI. Piper Sandler lifted their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Thursday. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $179.67.

Masimo Trading Up 1.4 %

NASDAQ MASI opened at $172.29 on Friday. Masimo has a 1-year low of $101.61 and a 1-year high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average of $169.23 and a 200-day moving average of $140.13. The firm has a market cap of $9.22 billion, a PE ratio of 118.82 and a beta of 1.01.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the previous year, the company posted $0.63 EPS. Masimo’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, sell-side analysts forecast that Masimo will post 4.03 EPS for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.